Interpreting Key Trials

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Chad L. Deal, MD
Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic

Address: Chad L. Deal, MD, Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation,9500 Euclid Avenue, Cleveland, OH 44195

Pelin Batur, MD
Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Holly L. Thacker, MD, FACP
Departments of General Internal Medicine and Obstetrics and Gynecology; Head, Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic; Clinical Associate Professor of Medicine, Penn State University, Hershey, PA

Halle C.F. Moore, MD
Department of Hematology and Medical Oncology, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Address: Pelin Batur, MD, Department of Internal Medicine, Gault Women’s Health and Breast Pavilion, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail baturp@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Pelin Batur, MD
Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Holly L. Thacker, MD, FACP
Departments of General Internal Medicine and Obstetrics and Gynecology; Head, Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic; Clinical Associate Professor of Medicine, Penn State University, Hershey, PA

Halle C.F. Moore, MD
Department of Hematology and Medical Oncology, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Address: Pelin Batur, MD, Department of Internal Medicine, Gault Women’s Health and Breast Pavilion, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail baturp@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Pelin Batur, MD
Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Holly L. Thacker, MD, FACP
Departments of General Internal Medicine and Obstetrics and Gynecology; Head, Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic; Clinical Associate Professor of Medicine, Penn State University, Hershey, PA

Halle C.F. Moore, MD
Department of Hematology and Medical Oncology, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic

Address: Pelin Batur, MD, Department of Internal Medicine, Gault Women’s Health and Breast Pavilion, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail baturp@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Craig R. Asher, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Allan L. Klein, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Allan L. Klein, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: kleina@ccf.org

Craig R. Asher, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Allan L. Klein, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Allan L. Klein, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: kleina@ccf.org

Craig R. Asher, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Allan L. Klein, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Allan L. Klein, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: kleina@ccf.org

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail bhattd@ccf.org

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail bhattd@ccf.org

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Gregory P. Gerschutz, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Deepak L. Bhatt, MD
Program Director, Interventional Cardiology Fellowship, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Deepak L. Bhatt, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail bhattd@ccf.org

Dr. Bhatt has indicated that he has received grant or research support from the Bristol-Myers Squibb and Sanofi-Synthelabo corporations.

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Derek P. Chew, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic

David J. Moliterno, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: David J. Moliterno, MD, Department of Cardiovascular Medicine, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; molited@ccf.org

Dr. Moliterno has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.

Stephen Pavia, MD
Department of Cardiology, Cleveland Clinic

Bruce L. Wilkoff, MD
Department of Cardiology, Cleveland Clinic

Address: Bruce L. Wiikoff, MD, Department of Cardiology, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Wilkoff has received grant support from and is on the advisory boards of Guidant, Medtronic, and St. Jude.

Stephen Pavia, MD
Department of Cardiology, Cleveland Clinic

Bruce L. Wilkoff, MD
Department of Cardiology, Cleveland Clinic

Address: Bruce L. Wiikoff, MD, Department of Cardiology, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Wilkoff has received grant support from and is on the advisory boards of Guidant, Medtronic, and St. Jude.

Stephen Pavia, MD
Department of Cardiology, Cleveland Clinic

Bruce L. Wilkoff, MD
Department of Cardiology, Cleveland Clinic

Address: Bruce L. Wiikoff, MD, Department of Cardiology, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Wilkoff has received grant support from and is on the advisory boards of Guidant, Medtronic, and St. Jude.

Herbert P. Wiedemann, MD
Chairman, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; site principal investigator and member of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) ARDS Network

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; investigator, NHLBI ARDS Network

Address: Herbert P. Wiedemann, MD, Department of Pulmonary and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; wiedemh@ccf.org

Herbert P. Wiedemann, MD
Chairman, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; site principal investigator and member of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) ARDS Network

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; investigator, NHLBI ARDS Network

Address: Herbert P. Wiedemann, MD, Department of Pulmonary and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; wiedemh@ccf.org

Herbert P. Wiedemann, MD
Chairman, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; site principal investigator and member of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) ARDS Network

Alejandro C. Arroliga, MD
Head, Section of Critical Care Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic; investigator, NHLBI ARDS Network

Address: Herbert P. Wiedemann, MD, Department of Pulmonary and Critical Care Medicine, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; wiedemh@ccf.org

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.